



PDL Changes submission to DUR Board
July 2008

PDL Additions without Clinical Edits

None

PDL Additions with Clinical Edits

Rationale: To ensure appropriate usage

Actoplus Met 15/500	QL=90
Actoplus Met 15/850	QL=60
Dermotic	QL=20 ml
Epifoam	QL=10 g
Hydrocodone/APAP 10/660	QL=120
Hydrocodone/APAP 5/325	QL=270
Hydrocodone/APAP 7.5/325	QL=240
Hypercare 20%	QL=60 ml
Intelence	QL=60
Lufyllin	QL=360
Pediotic	QL=7.5 ml
SSKI	QL=30 ml
Tikosyn	QL=60
Uniphyl	QL=30
Zolene HC otic	QL=10 ml
Zotane HC otic	QL=10 ml

Addition of Utilization Edits to existing PDL medications

Rationale: To ensure appropriate usage

Pulmicort Respules	Change of Age Limit ≤ 6 yrs to Age Limit ≤ 4 yrs
Non-Preferred PPIs	QL=4 months total treatment per 12 months

Removal of Non-Preferred Status

Lipitor	PDL options include simvastatin and lovastatin products as first line agents
---------	--